Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b Double-Blind Placebo-Controlled Study of Peresolimab in Rheumatoid Arthritis
jRCT2031220628Phase 2Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of peresolimab in rheumatoid arthritis (RA) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: ACR20 response at Week 12. Started Feb 2023; status: active, not recruiting.
02
Drugs
peresolimab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCT2031220628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220628.